Literature DB >> 34242744

CUSTOMIZING LOCAL AND SYSTEMIC THERAPIES FOR WOMEN WITH EARLY BREAST CANCER: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

H J Burstein1, G Curigliano2, B Thürlimann3, W P Weber4, P Poortmans5, M Regan6, H J Senn7, E P Winer6, M Gnant8.   

Abstract

The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held virtually, owing to the global COVID19 pandemic. More than 3,300 participants took part in this important bi-annual critical review of the "state of the art" in the multidisciplinary care of early-stage breast cancer. Seventy-four expert panelists (see Appendix) from all continents discussed and commented on the previously elaborated consensus questions as well as many key questions on early breast cancer diagnosis and treatment asked by the audience. The theme of this year's Conference was "Customizing local and systemic therapies." A well-organized program of pre-recorded symposia, live panel discussions, and real-time panel voting results drew a worldwide audience of thousands, reflecting the far-reaching impact of breast cancer on every continent. The interactive technology platform allowed, for the first time, audience members to ask direct questions to panelists, and to weigh in with their own vote on several key panel questions. A hallmark of this meeting was to focus on customized recommendations for treatment of early stage breast cancer. There is increasing recognition that the care of a breast cancer patient depends on highly individualized clinical features, including the stage at presentation, the biological subset of breast cancer, the genetic factors that may underlie breast cancer risk, the genomic signatures that inform treatment recommendations, the extent of response prior to surgery in patients who receive neoadjuvant therapy, and patient preferences. This customized approach to treatment requires integration of clinical care between patients and radiology, pathology, genetics, and surgical, medical, and radiation oncology providers. It also requires a dynamic response from clinicians as they encounter accumulating clinical information at the time of diagnosis and then serially with each step in the treatment plan and follow-up, reflecting patient experiences and treatment response.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Year:  2021        PMID: 34242744     DOI: 10.1016/j.annonc.2021.06.023

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  50 in total

1.  A Systematic Review and Meta-Analysis on the Role of Repeat Breast-Conserving Surgery for the Management of Ipsilateral Breast Cancer Recurrence.

Authors:  Clare Josephine Tollan; Eirini Pantiora; Antonios Valachis; Andreas Karakatsanis; Marios Konstantinos Tasoulis
Journal:  Ann Surg Oncol       Date:  2022-07-18       Impact factor: 4.339

2.  Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysis.

Authors:  Dalang Fang; Yanting Li; Yanghong Li; Yongcheng Chen; Qianfang Huang; Zhizhai Luo; Jinghua Chen; Yingjin Li; Zaizhi Wu; Yuanlu Huang; Yanfei Ma
Journal:  Gland Surg       Date:  2022-06

3.  Rates of pathologic nodal disease among cN0 and cN1 patients undergoing routine axillary ultrasound and neoadjuvant chemotherapy.

Authors:  Anna Weiss; Claire King; Julie Vincuilla; Tonia Parker; Leah Portnow; Faina Nakhlis; Laura Dominici; Elizabeth A Mittendorf; Tari A King
Journal:  Breast Cancer Res Treat       Date:  2022-07-28       Impact factor: 4.624

Review 4.  Regional Nodal Management in the Setting of Up-Front Surgery.

Authors:  Lior Z Braunstein; Monica Morrow
Journal:  Semin Radiat Oncol       Date:  2022-07       Impact factor: 5.421

5.  Trends of cancer mortality in Xi'an City, China: 2005-2020.

Authors:  Ning Chen; Xiao-Yu Zhang; Lin-Lin Ma; Guo-Dong Zhao; Yu-Xiang Yan
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-14       Impact factor: 4.322

6.  Pathological Diagnosis, Work-Up and Reporting of Breast Cancer 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.

Authors:  Gábor Cserni; Monika Francz; Balázs Járay; Endre Kálmán; Ilona Kovács; Tibor Krenács; Erika Tóth; Nóra Udvarhelyi; László Vass; András Vörös; Ana Krivokuca; Karol Kajo; Katarína Kajová Macháleková; Janina Kulka
Journal:  Pathol Oncol Res       Date:  2022-06-27       Impact factor: 2.874

7.  Synchronous Operable Pancreatic and Breast Cancer Without Genetic Mutation: A Literature Review and Discussion.

Authors:  Adam Ofri; Danika Zuidersma; Connie I Diakos; Amanda Stevanovic; Matthew Wong; Samriti Sood; Jaswinder S Samra; Anthony J Gill; Anubhav Mittal
Journal:  Front Surg       Date:  2022-06-24

Review 8.  Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.

Authors:  Qiaorui Tan; Sha Yin; Dongdong Zhou; Yajing Chi; Xiaochu Man; Huihui Li
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

9.  Modern Breast Cancer Surgery 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.

Authors:  Zoltán Mátrai; Péter Kelemen; Csaba Kósa; Róbert Maráz; Attila Paszt; Gábor Pavlovics; Ákos Sávolt; Zsolt Simonka; Dezső Tóth; Miklós Kásler; Andrey Kaprin; Petr Krivorotko; Ferenc Vicko; Piotr Pluta; Agnieszka Kolacinska-Wow; Dawid Murawa; Jerzy Jankau; Slawomir Ciesla; Daniel Dyttert; Martin Sabol; Andrii Zhygulin; Artur Avetisyan; Alexander Bessonov; György Lázár
Journal:  Pathol Oncol Res       Date:  2022-06-15       Impact factor: 2.874

10.  Low Rates of Medical Oncology Consultation for Older Women (≥ 70 Years) with Newly Diagnosed, Non-Metastatic Breast Cancer: A Population-Based Study.

Authors:  Gary Ko; Julie Hallet; Katarzyna J Jerzak; Wing Chan; Natalie Coburn; Victoria Barabash; Frances C Wright; Nicole J Look Hong
Journal:  Ann Surg Oncol       Date:  2022-10-18       Impact factor: 4.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.